DrugPatentWatch Database Preview
Drugs in Development Information for AZD3293
» See Plans and Pricing
What is the drug development status for AZD3293?
AZD3293 is an investigational drug.
There have been 15 clinical trials for AZD3293.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.
The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are AstraZeneca, Eli Lilly and Company, and Parexel.
There are twenty-three US patents protecting this investigational drug and two hundred and nineteen international patents.
Summary for AZD3293
| US Patents | 23 |
| International Patents | 219 |
| US Patent Applications | 72 |
| WIPO Patent Applications | 62 |
| Japanese Patent Applications | 25 |
| Clinical Trial Progress | Phase 1 (2016-07-01) |
| Vendors | 23 |
Recent Clinical Trials for AZD3293
| Title | Sponsor | Phase |
|---|---|---|
| A Study of LY3314814 in Early Alzheimer's Disease Dementia | AstraZeneca | Phase 3 |
| A Study of LY3314814 in Early Alzheimer's Disease Dementia | Eli Lilly and Company | Phase 3 |
| A Study of LY3314814 in Healthy Participants When Taken With Rosuvastatin | AstraZeneca | Phase 1 |
Clinical Trial Summary for AZD3293
Top disease conditions for AZD3293
Top clinical trial sponsors for AZD3293
US Patents for AZD3293
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD3293 | Get Started for $10 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder | Axovant Sciences GmbH (Basel, CH) | Get Started for $10 |
| AZD3293 | Get Started for $10 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | Axovant Sciences GmbH (Basel, CH) | Get Started for $10 |
| AZD3293 | Get Started for $10 | Anti-Tau antibodies and methods of use | Genentech, Inc. (South San Francisco, CA) AC Immune SA (Lausanne, CH) | Get Started for $10 |
| AZD3293 | Get Started for $10 | Compounds, compositions and methods | Denali Therapeutics Inc. (South San Francisco, CA) | Get Started for $10 |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD3293
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD3293 | Argentina | AR104982 | 2035-06-12 | Get Started for $10 |
| AZD3293 | Australia | AU2016276966 | 2035-06-12 | Get Started for $10 |
| AZD3293 | Canada | CA2989343 | 2035-06-12 | Get Started for $10 |
| AZD3293 | China | CN109562085 | 2035-06-12 | Get Started for $10 |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
